Artemisinin, also known as Qinghaosu (Chinese: 青蒿素), isolated from artemisia annua, is a drug that possess the most rapid action of all current drugs against Plasmodium falciparum malaria. It is safe and effective in clinic. In the present study, we found that artemisinin promoted the survial of various cell types such as PC12 cells and primary cortical cultured neurons from oxidative insults. For example, pretreatment of PC12 cells with artemisinin significantly suppressed SNP/H 2 O 2 -induced cell death by decreasing the production of intracellular reactive oxygen species (ROS), preventing the decline of mitochondrial membrane potential, restoring abnormal changes in nuclear morphology and reducing LDH and caspase 3/7 activities. Western blotting analysis showed that artemisinin was able to stimulate the phosphorylation/activation of extracellular regulated protein kinases (ERK) kinase, AMPK and CREB while had no effect on the Akt pathway. In addition, ERK and AMPK signaling pathway inhibitors attenuated the protective effect of artemisinin whereas the PI3K inhibitor LY294002 had no effect. Taken together, these results suggest that artemisinin as a potential neuroprotectant is able to suppress varous oxdative stress-induced neuronal cell death via the activation of ERK/AMPK signaling. Our results offer support for the potential development of artemisinin to prevent neuronal degenerative disorders. Keywords: artemisinin; oxidative insults; neuronal cells; AMPK Acknowledgements: This work was supported by NFSC (No 31371088), FDCT 016/2016/A1, SRG2015-00004 and MYRG2016-00052 from University of Macau.
E-mail: chenmr928@163.com Ischemic stroke is a common cause of long-term disability or even death. Suspended moxibustion, an indirect form of moxibustion, is when moxibustion is placed superficially over the skin without physically contact. Suspended moxibustion has been used to treat stroke patients, while the effect of traditional suspended moxibustion has recently been improved with the development of heat-sensitive moxibustion, but no strong evidence of its therapeutic effectiveness is documented to date. The theoretical basis for heat-sensitive moxibustion is that the acupoints are activated from the resting state to the sensitized state during pathological processes thus become heat sensitive. Moxibustion placed above a heat-sensitive acupoint can induce not only internal heat-sensation but also physically detectable elevated temperature at distant locations away from the suspended moxibustion acupoint. In this study, we compared the effects and investigated mechanism of moxibustion at acupoint Dazhui (DU14) with (heat-sensitive moxibustion, HSM) or without tail temperature increase (non-heat-sensitive moxibustion, NHSM). We found that HSM decreased tail-flick latency, increased neurological function score, decreased infarct volume, reduced inflammatory cells infiltration, and decreased inflammatory mediators and the expression of NF-κB signaling pathway in rats with focal cerebral ischemia/reperfusion injury. Our experimental findings indicated that HSM can significantly attenuate inflammation and promote repair after focal cerebral ischemia/reperfusion injury. Keywords: suspended moxibustion; middle cerebral artery occlusion; cerebral ischemia/reperfusion injury; infarct volume; inflammatory cells; inflammatory mediators ; NF-κB p65S1. In the present study, we found that FTY720 protected against oxygenglucose deprivation/reoxygenation (OGD)-induced cellular injury and inhibited the up-regulation of S 1 PR 3 in astrocytes. Further study revealed that FTY720 prevented OGD-induced the elevations of Toll-like receptor 2 and 4 (TLR2 , TLR4) and advanced glycation end-products receptor (RAGE), and inhibited phosphatidyl-inositol 3 kinase (PI3K) phosphorylation and nuclear p65 activation. Subsequently, FTY720 significantly decreased inflammatory cytokines secretion including high mobility group box 1(HMGB1), tumor necrosis factor-α (TNF-α) and inducible nitric oxide synthase (iNOS) from astrocytes. Transfecting S1pr3 antisense oligonucleotide into astocytes could abolish all of the above-mentioned effects of FTY720, suggesting that S 1 PR 3 was the target for FTY720. Moreover, not RAGE monoclonal antibody but TLR2,4 antagonist could block the protective effects of FTY720. The results from ischemic stroke model of rats confirmed that FTY720 reduced the brain infarct volumes, inhibited astrocyte activations in periinfarct area and thereby decreased the levels of inflammatory cytokines in serum. Taken together, the present study reveals that FTY720 acting on S 1 PR 3 protected against brain ischemia-induced astrocytic activation and injury via TLR2,4/ PI3K/NF-κB signaling pathway. Our findings reveal a novel astrocyte-mediated neuroinflammation mechanism depending on S 1 PRs, and suggest that S 1 PRs might be a potential target for ischemia stroke. E-mail: chennh@imm.ac.cn Depression is a devastating mental disorder and major depressive disorder afflicts about 16% of the world population at some point in their lives. Although the molecular mechanisms underlying depression are still largely unclear, previous studies suggested that modulators of mTORC1 signaling network would have beneficial neuroprotective and antidepressant effects. This article aims to (1) review research actuality of depression and antidepressants. (2) provide an overview of the architecture and biology of mTORC1 in brain. (3) summarize the recent advances of the role of mTORC1 signaling network in depression and the potential therapeutic strategies resulting from the modulation of this process. The upstream regulators of the mTORC1 signaling network for antidepressants include pathways involved in activation of AMPA receptor, PI3K-Akt, ERK-MAPKs, and CREB-BDNF; dysregulation of downstream targets of mTORC1 signaling network, such as synaptic protein synthesis, the phosphorylation of eEF2, and autophagy would be associated with stress and depression. (4) point towards future research directions. Faster-acting antidepressants are needed, particularly for suicide-risk patients for current therapies for depression. It has recently been shown that treatment with new agents, for example, ketamine or (2R, 6R)-HNK (the metabolism of ketamine) results in an improvement in depressive behaviors within hours and lasts up to two weeks of dosing patients who are resistant to typical antidepressants, which have limited efficacy and delayed response times of weeks to months. The prospects for next-generation rapid-acting antidepressants would focus on developing more selective AMPA receptor agonists that activate the mTORC1 signaling pathway free of ketamine's adverse effects. Keywords: depression; antidepressant; mammalian Target of Rapamycin Complex 1 (mTORC1) signaling network; α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor; ketamine; brain-derived neurotrophic factor (BDNF); synaptic protein synthesis; eukaryotic elongation factor 2 (eEF2); autophagy E-mail: chennh@imm.ac.cn Major depression is thought to originate from maladaptation to adverse events, particularly when impairments occur in mood-related brain regions. Hypothalamuspituitary-adrenal (HPA) axis is one of the major systems involved in physiological stress response. HPA axis dysfunction and high glucocorticoid concentrations play an important role in the pathogenesis of depression. In addition, astrocytic disability and dysfunction of neurotrophin brain-derived neurotrophin factor (BDNF) greatly influence the development of depression and anxiety disorders. Therefore, we investigated whether depressive-like and anxiety-like behaviors manifest in the absence of glucocorticoid production and circulation in adrenalectomized (ADX) rats after chronic mild stress (CMS) exposure and its potential molecular mechanisms. The results demonstrate that glucocorticoid-controlled rats showed anxiety-like behaviors but not depression-like behaviors after CMS. Molecular and cellular changes included the decreased BDNF in the hippocampus, astrocytic dysfunction with connexin43 (cx43) decreasing and abnormality in gap junction in prefrontal cortex (PFC). Interestingly, we did not find any changes in glucocorticoid receptor (GR) or its chaperone protein FK506 binding protein 51 (FKBP5) expression levels in the hippocampus or PFC in ADX rats subjected to CMS. In conclusion, the production and circulation of glucocorticoids are one of the contributing factors in the development of depression-like behaviors in response to CMS. In contrast, the effects of CMS on anxiety-like behaviors are independent of the presence of circulating glucocorticoids. Meanwhile, stress decreased GR expression and enhanced FKBP5 expression via higher glucocorticoids exposure. Gap junction dysfunction and changes in BDNF may be associated with anxiety-like behaviors. Keywords: depression; chronic mild stress; GR; FKBP5; BDNF; Gap junction
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Interventional effect of prostaglandin E1 on the expression of Apaf-1 and TLR4 in the rats with cerebral ischemia-reperfusion injury Wei-juan DAI * , Guo-an ZHANG, Huan LI, Xu WANG, Xu-dong XU, Fan-he ZHU We demonstrated that once daily administration of trehalose was efficacious and defined the PK associated with efficacy. These PK parameters can be targeted in the clinical development of trehalose. Keywords: Trehalose; Parkinson's disease; disease modification
